Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1958 1
1959 1
1960 1
1961 3
1962 2
1963 2
1964 1
1965 2
1966 4
1967 4
1968 6
1969 3
1970 7
1971 9
1972 6
1973 6
1974 5
1975 3
1976 5
1977 2
1978 2
1979 2
1980 8
1981 13
1982 6
1983 7
1984 5
1985 8
1986 8
1987 12
1988 10
1989 12
1990 10
1991 15
1992 15
1993 19
1994 23
1995 28
1996 28
1997 29
1998 42
1999 36
2000 41
2001 39
2002 29
2003 40
2004 23
2005 17
2006 26
2007 13
2008 24
2009 26
2010 15
2011 19
2012 26
2013 30
2014 29
2015 42
2016 35
2017 35
2018 43
2019 45
2020 63
2021 63
2022 40
2023 47
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

1,142 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
Siena S, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, Yamaguchi K, Nishina T, Fakih M, Elez E, Rodriguez J, Ciardiello F, Komatsu Y, Esaki T, Chung K, Wainberg Z, Sartore-Bianchi A, Saxena K, Yamamoto E, Bako E, Okuda Y, Shahidi J, Grothey A, Yoshino T; DESTINY-CRC01 investigators. Siena S, et al. Among authors: okuda y. Lancet Oncol. 2021 Jun;22(6):779-789. doi: 10.1016/S1470-2045(21)00086-3. Epub 2021 May 4. Lancet Oncol. 2021. PMID: 33961795 Clinical Trial.
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.
Yoshino T, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, Yamaguchi K, Nishina T, Wainberg Z, Elez E, Rodriguez J, Fakih M, Ciardiello F, Saxena K, Kobayashi K, Bako E, Okuda Y, Meinhardt G, Grothey A, Siena S; DESTINY-CRC01 investigators. Yoshino T, et al. Among authors: okuda y. Nat Commun. 2023 Jun 7;14(1):3332. doi: 10.1038/s41467-023-38032-4. Nat Commun. 2023. PMID: 37286557 Free PMC article.
SimWars.
Okuda Y, Godwin SA, Jacobson L, Wang E, Weingart S. Okuda Y, et al. J Emerg Med. 2014 Nov;47(5):586-93. doi: 10.1016/j.jemermed.2014.06.058. Epub 2014 Sep 13. J Emerg Med. 2014. PMID: 25224173
Developing diagnostic reference levels in Japan.
Kanda R, Akahane M, Koba Y, Chang W, Akahane K, Okuda Y, Hosono M. Kanda R, et al. Among authors: okuda y. Jpn J Radiol. 2021 Apr;39(4):307-314. doi: 10.1007/s11604-020-01066-5. Epub 2020 Nov 19. Jpn J Radiol. 2021. PMID: 33211263 Free PMC article. No abstract available.
1,142 results